Market Cap 329.72M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 7.34
Forward PE 5.21
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 2,217,800
Avg Vol 723,378
Day's Range N/A - N/A
Shares Out 51.28M
Stochastic %K 4%
Beta 1.67
Analysts Strong Sell
Price Target $20.50

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
Pharma3000
Pharma3000 Sep. 16 at 12:55 PM
$ABEO Today a lot of investors will be adding to their positions. I don’t expect another chance to buy this stock under $6 for years if the company executes as planned. 🔥📈💡
0 · Reply
Damian23
Damian23 Sep. 16 at 7:43 AM
$ABEO So Krystal has 4B valuation for a mere 100M top line revenue in 2025, Abeo has a 330M MC for a potential 100M revenue in 2026.... And people bullish on Krystal instead of Abeo??? Doesnt make any sense to me, good luck to Krystal shareholders,
1 · Reply
alexpitti
alexpitti Sep. 16 at 4:16 AM
Any sort of minor news event like a slight change in the VYJUVEK label can knock $ABEO stock down when we are still waiting for the first treatment. The underlying cause is the lack of sales. This launch needs to start treating patients in the next 2 weeks and increase treatments in October and November.
0 · Reply
creditgoo
creditgoo Sep. 16 at 1:13 AM
$ABEO the bulls have finally disappeared
0 · Reply
Tjcmd
Tjcmd Sep. 16 at 1:10 AM
$ABEO will krystal get a PRV for the label expansion?
1 · Reply
Arcides
Arcides Sep. 16 at 12:01 AM
$ABEO this one made the worst day in a year...garbage.
0 · Reply
creditgoo
creditgoo Sep. 15 at 10:51 PM
$ABEO almost the biggest red day of the year. And its Monday
0 · Reply
alexpitti
alexpitti Sep. 15 at 10:48 PM
this is my thesis $ABEO
2 · Reply
HedgiesLivesMatter
HedgiesLivesMatter Sep. 15 at 10:18 PM
$ABEO thank you shorties.
0 · Reply
alexpitti
alexpitti Sep. 15 at 9:38 PM
I'm sure some are concerned with Abeona treating its first patient, but it takes a couple more weeks to treat the first patient than normal. 25 days is not some iron law that perfectly aligns with surgical procedures. $ABEO First procedure should occur late september.
0 · Reply
Latest News on ABEO
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 4 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript


US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 5 months ago

US FDA approves Abeona's skin disorder therapy


Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 5 months ago

Pz-Cel Has Massive Potential For RDEB Patients


Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 6 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript


Pharma3000
Pharma3000 Sep. 16 at 12:55 PM
$ABEO Today a lot of investors will be adding to their positions. I don’t expect another chance to buy this stock under $6 for years if the company executes as planned. 🔥📈💡
0 · Reply
Damian23
Damian23 Sep. 16 at 7:43 AM
$ABEO So Krystal has 4B valuation for a mere 100M top line revenue in 2025, Abeo has a 330M MC for a potential 100M revenue in 2026.... And people bullish on Krystal instead of Abeo??? Doesnt make any sense to me, good luck to Krystal shareholders,
1 · Reply
alexpitti
alexpitti Sep. 16 at 4:16 AM
Any sort of minor news event like a slight change in the VYJUVEK label can knock $ABEO stock down when we are still waiting for the first treatment. The underlying cause is the lack of sales. This launch needs to start treating patients in the next 2 weeks and increase treatments in October and November.
0 · Reply
creditgoo
creditgoo Sep. 16 at 1:13 AM
$ABEO the bulls have finally disappeared
0 · Reply
Tjcmd
Tjcmd Sep. 16 at 1:10 AM
$ABEO will krystal get a PRV for the label expansion?
1 · Reply
Arcides
Arcides Sep. 16 at 12:01 AM
$ABEO this one made the worst day in a year...garbage.
0 · Reply
creditgoo
creditgoo Sep. 15 at 10:51 PM
$ABEO almost the biggest red day of the year. And its Monday
0 · Reply
alexpitti
alexpitti Sep. 15 at 10:48 PM
this is my thesis $ABEO
2 · Reply
HedgiesLivesMatter
HedgiesLivesMatter Sep. 15 at 10:18 PM
$ABEO thank you shorties.
0 · Reply
alexpitti
alexpitti Sep. 15 at 9:38 PM
I'm sure some are concerned with Abeona treating its first patient, but it takes a couple more weeks to treat the first patient than normal. 25 days is not some iron law that perfectly aligns with surgical procedures. $ABEO First procedure should occur late september.
0 · Reply
fede5910
fede5910 Sep. 15 at 9:32 PM
$ABEO Krystal today operated 708,913 shares at an average of 150 dollars per share, which represents 106,336,950 dollars. If we divide this by 6, the approximate value of Abeo, we get a volume of 17,722,825 shares of Abeo. Imagine when the investors from Krystal take a look at Abeo and decide to shift their investments here; Abeo is going to soar. Today's value of Abeo is approximately 6, future minimum value 30 multiplied by 5. I don't see how Krystal can multiply its value by 5, and it is far from the 200 dollars it used to be worth. It's just a matter of waiting and letting the stars align: first patient, second patient, patient 10, patient 20, patient 100, step by step, soon all of this will happen. Go Abeo...
1 · Reply
fede5910
fede5910 Sep. 15 at 9:09 PM
$ABEO In this market, good news gradually increases the price, and sometimes it doesn’t rise enough due to profit-taking. There are also bad news in this market that are operated by short sellers; they amplify the bad news and make unsophisticated investors believe that disaster is looming, and under the threat of losing a lot, they play the game that the shorts want. Here, the only reality is that the first patient has not yet appeared, and that is not being discussed; it’s bad news, no, it’s not news, it’s assumption, it’s speculation, which, amplified by the shorts, seems like the end of the world. I remind everyone that the first car Ford released to the market had no reverse gear, and look at how far Ford has come. Come on ABEO, this is just the beginning.
1 · Reply
perision
perision Sep. 15 at 8:49 PM
$ABEO Big sell signal…
1 · Reply
alcacer123
alcacer123 Sep. 15 at 8:27 PM
$ABEO It would be nice, ABEO's CEO, if you could start with the first patient, then the second. It's been four months since they hired a global company, and they have 120 people earning salaries. I think it's time to start doing what they came to do. Just their job. That might be asking too much. Your company is under attack from a very obvious MM movement. And Krystal has just consolidated. I hope after the spectacular conferences we can move on to the facts.
0 · Reply
Florestan
Florestan Sep. 15 at 8:16 PM
$ABEO what does label expansion for DEB from Vyjuvek for younger population has anything to do with unclosed wounds from rDEB? I want to pin the drop to it but I just can't find the logic matching.
2 · Reply
Zweagel91
Zweagel91 Sep. 15 at 7:54 PM
$ABEO the only difference I see is a lot more convenience for Vyjuvek patients. Vyjuvek focusses on smaller and medium size wounds, and it does not produce permanent wound healing. Zevaskyn on the other hand has proven long term/permanent wound healing, and focusses on the large and most terrible wounds which have been open for years. So I am not in the least bit worried. This is just the volatility of the biotech sector. JMO
2 · Reply
commoncentsinvestor
commoncentsinvestor Sep. 15 at 7:51 PM
$ABEO VYJUVEK is a weekly-dosed topical gel for widespread wound treatment in DEB, while Zevaskyn is a single-surgical-application, autologous cell-based gene therapy for treating specific large, chronic wounds in RDEB. Zevaskyn uses the patient's own cells to create a customized sheet applied surgically, whereas Vyjuvek delivers a gene therapy via a viral vector in a gel format. The choice between them depends on the specific type and severity of epidermolysis bullosa (EB) a patient has, with Vyjuvek suitable for many DEB types and Zevaskyn focused on severe RDEB cases.
1 · Reply
Buyorsell4321
Buyorsell4321 Sep. 15 at 7:40 PM
$ABEO what a deal.
0 · Reply
Po556677
Po556677 Sep. 15 at 7:27 PM
$ABEO would love to hear from some of the long timers in abeo regarding the news from krys
1 · Reply
creditgoo
creditgoo Sep. 15 at 6:39 PM
$ABEO below 5 eow is a guarantee
0 · Reply
Orlandotrader
Orlandotrader Sep. 15 at 6:28 PM
$ABEO Can’t say I feel great buying 500 at 7$ but will add another 500 now as RSI is getting close to 30. Will add 1000 at 5$ or below. We shall Rise!!!
0 · Reply
creditgoo
creditgoo Sep. 15 at 6:06 PM
$ABEO didnt expect to see this down 15% in 2 days but easy easy money
0 · Reply